New trial
Zanzalintinib Maintenance in High Grade Neuroendocrine Neoplasms
- Trial ID
- NCT06926634 on ClinicalTrials.gov
- Cancer type
- Neuroendocrine Neoplasms
- Location
- 2 Locations
- Published in
- New in Oncology - May 14, 2025
Washington University School of Medicine is evaluating zanzalintinib as a maintenance therapy following initial chemotherapy to extend progression-free survival in patients with high-grade neuroendocrine neoplasms. The trial administers daily oral zanzalintinib in 28-day cycles for up to 3 years.
More in neuroendocrine and adrenal tumors
-
Trial result · Oct 15, 2026 · NCT00107289
Single ¹³¹I-MIBG (NET-targeted radiopharmaceutical) + single autologous stem cell rescue shows feasible engraftment but low response in resistant neuroblastoma -
Trial result · Aug 27, 2026 · NCT03972488
¹⁷⁷Lu-DOTATATE (SSTR-targeted PRRT) extends PFS ~14 months vs high-dose octreotide in 1L G2–G3 GEP-NETs -
New trial · Aug 27, 2026 · NCT07743138
Phase 2 ivonescimab PD-1×VEGF bispecific antibody in previously treated ACC/PPGL -
Trial result · Aug 6, 2026 · NCT03049189
[177Lu]Lu-edotreotide (SSTR2-targeted PRRT) beats everolimus on PFS in progressive GEP-NETs (COMPETE) -
New trial · Jul 16, 2026 · NCT07661420
Phase 1 211At‑MABG targeted alpha radiotherapy (NET/norepinephrine transporter–avid) in advanced NETs